priced a public offering of 6.1 million shares at $2.30 each looking to raise $14 million...closed its public offering of 8 million common shares at $4 per share...priced a public offering of about 4.7 million shares of common stock at $18 per share
Type of Financing January February Total ($M) Public offerings 2,305.0 269.1 2,574.1 Public/other 530.4 238.9 769.3 Private biotechs 210.2 161.9 372.0 Total ($M) 3,045.6 669.9 3,715.4 Notes: Public offerings = Initial, follow-on
Somewhere along the way from the heady days of the dot-com era in 2000 the "magic" of achieving a successful biotech initial public offering (IPO) seems to have been lost
By Peter Winter | BioWorld Insight | Monday, March 4, 2013
The company disclosed its plan to begin a public offering to raise $125 million more, pursuant to a shelf registration last week. (See BioWorld Today, Feb 22, 2013...Tesaro Inc., of Waltham, Mass., priced an underwritten public offering of about 4.7 million shares of common stock at $18 per share
In the fourth quarter, Isis recorded an $18.4 million gain following the initial public offering by La Jolla, Calif.-based Regulus Therapeutics Inc., which Isis co-founded
Shares of Hyperion (NASDAQ:HPTX), which began trading last year following the firm's $50 million initial public offering, closed Wednesday at $18.93, down 37 cents. (See BioWorld Today, July 27, 2012, and Feb. 4, 2013
Oncolytics Biotech Inc., of Calgary, Alberta, closed its previously announced underwritten public offering of 8 million common shares, at a price of $40 per common share
went small with its first financing in more than five years, pricing an underwritten public offering of 6.1 million shares at $2.30 each – a 15 percent discount to Thursday's closing price – and seeking to raise just $14 million
By Marie Powers | BioWorld Today | Monday, February 25, 2013
disclosed an S-1 filing with the SEC for an initial public offering (IPO) of its common stock, expected to trade on the Nasdaq market under the symbol "AMBI
By Marie Powers | BioWorld Today | Friday, February 22, 2013
topped up its cash with a $75 million public offering to support development and clinical trials of its oncology pipeline products...public offering (IPO) in June 2012, and priced within its expected range, a coup for a biotech IPO in an uncertain economy
By Catherine Shaffer | BioWorld Today | Friday, February 22, 2013
Novelos Therapeutics, Inc., of Madison, Wisc., said it closed a public offering of 11 million units at $0.50 per unit for gross proceeds of $5.5 million
In October, Puma beefed up its balance sheet with a public offering of 8.6 million shares, including 1.1 million sold as overallotments, at $16 per share for net proceeds of about $129.1 million. (See BioWorld Today, Oct. 22, 2012.) Puma acquired neratinib, an oral, irreversible tyrosine kinase inhibitor, from Pfizer Inc
By Catherine Shaffer | BioWorld Today | Thursday, February 21, 2013
Aiming to start pivotal trials with its therapy for benign prostatic hyperplasia (BPH) before the end of the year, Sophiris Bio Inc. (formerly Protox Therapeutics Inc.) filed for an initial public offering (IPO) that specifies neither the number of shares nor the price range
By Randy Osborne | BioWorld Today | Wednesday, February 20, 2013
AVEO recently completed a public offering of 6.6 million shares of stock at $7.50 per share, or about $50 million in gross proceeds. (See BioWorld Today, Jan. 18, 2013.) Looking ahead, AVEO is branching out beyond kidney cancer
By Catherine Shaffer | BioWorld Today | Thursday, February 14, 2013
Novelos Therapeutics Inc., of Madison, Wisc., said it priced a public offering of 11 million units at $0.50 per unit for gross proceeds of $5.5 million
By Marie Powers | BioWorld Today | Thursday, February 14, 2013
priced a public offering of 6.1 million shares at $2.30 each looking to raise $14 million...closed its public offering of 8 million common shares at $4 per share...priced a public offering of about 4.7 million shares of common stock at $18 per share